Pulmonary Drugs Global Market Report 2025

Description

Pulmonary drugs are medications designed to target the respiratory system to enhance lung function, reduce inflammation, and manage airway disorders. They are commonly used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main classes of pulmonary drugs include inhaled corticosteroids, long-acting beta-2 agonists, antihistamines, vasodilators, short-acting beta-2 agonists, and others. Inhaled corticosteroids are anti-inflammatory medications delivered directly to the lungs via inhalers, helping to manage chronic respiratory conditions such as asthma and COPD by reducing airway inflammation and preventing flare-ups. These drugs are used for indications such as asthma, COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and more. They are distributed through various channels, including retail pharmacies, online pharmacies, and hospital pharmacies.

The pulmonary drugs market research report is one of a series of new reports from The Business Research Company that provides pulmonary drugs market statistics, including the pulmonary drugs industry global market size, regional shares, competitors with the pulmonary drugs market share, detailed pulmonary drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the pulmonary drugs industry. This pulmonary drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pulmonary drugs market size has grown strongly in recent years. It will grow from$54.28 billion in 2024 to $57.53 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth during the historic period can be attributed to the rise in the prevalence of respiratory diseases, an increase in smoking rates, the growing geriatric population, expanded healthcare access, and the surge in pollution levels.

The pulmonary drugs market size is expected to see strong growth in the next few years. It will grow to$71.91 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth during the forecast period can be attributed to the expansion of healthcare infrastructure, the rising prevalence of cardiovascular diseases, the growth of homecare treatments, increased awareness about pulmonary diseases, and the rising prevalence of asthma. Key trends expected during this period include technological advancements, AI-driven drug discovery, the adoption of smart inhalers, nanotechnology-based formulations, and developments in gene therapy.

The growing prevalence of respiratory diseases is expected to drive the expansion of the pulmonary drugs market. Respiratory disorders are medical conditions that affect the lungs and airways, hindering normal breathing and oxygen exchange. The incidence of respiratory disorders is rising due to factors such as smoking, which contributes to lung damage and chronic diseases. Pulmonary drugs are vital in managing these conditions by improving lung function, reducing inflammation, and alleviating airway obstruction, thus enhancing breathing. For example, in November 2023, the Bureau of Labor Statistics, a U.S.-based government agency, reported that the illness rate among private industry employers in 2022 rose to 45.2 cases per 10,000 full-time equivalent (FTE) workers, up from 37.7 cases in 2021. This increase was primarily due to a higher incidence of respiratory illnesses, which grew from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. As a result, the rising prevalence of respiratory diseases is fueling the growth of the pulmonary drugs market.

Leading companies in the pulmonary drugs market are focusing on developing innovative treatments, such as single-inhaler triple therapy (SITT), to improve treatment effectiveness, enhance patient adherence, and simplify medication regimens for better disease management. Single-inhaler triple therapy combines three different medications into one inhaler to more effectively manage chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD). For example, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, an India-based pharmaceutical company, introduced Trelegy Ellipta, India's first single-inhaler triple therapy for COPD patients. This therapy combines fluticasone furoate, umeclidinium, and vilanterol to improve lung function and reduce symptom flare-ups. The innovative Ellipta inhaler ensures accurate dosing and enhances patient adherence compared to multiple-inhaler therapies. With over 100 million COPD patients in India, this launch aims to simplify treatment and improve patient outcomes.

In September 2024, Roivant Sciences Ltd., a U.S.-based biotechnology company, acquired a pulmonary hypertension drug from Bayer AG for an undisclosed sum. This acquisition enables Roivant to expand its respiratory portfolio and advance innovative treatments for pulmonary hypertension, thus improving patient outcomes and addressing unmet medical needs. Bayer AG, a Germany-based company, manufactures pulmonary drugs, including treatments for respiratory conditions such as pulmonary hypertension.

Major players in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, and Circassia Pharmaceuticals plc.

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pulmonary drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pulmonary drugs market consists of the sales of inhalers, nebulizers, bronchodilators, anti-inflammatory agents, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pulmonary Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pulmonary drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pulmonary drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pulmonary drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Inhaled Corticosteroids; Long Acting Beta-2 Agonists; Antihistamines; Vasodilators; Short Acting Beta-2 Agonists; Other Drug Classes
2) By Indication: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Allergic Rhinitis; Pulmonary Arterial Hypertension; Cystic Fibrosis; Other Indications
3) By Distribution Channel: Retail Pharmacies; Online Pharmacies; Hospitals Pharmacies
Subsegments:
1) By Inhaled Corticosteroids: Beclomethasone; Budesonide; Fluticasone; Mometasone; Ciclesonide
2) By Long-Acting Beta-2 Agonists: Salmeterol; Formoterol; Indacaterol; Olodaterol; Vilanterol
3) By Antihistamines: Cetirizine; Loratadine; Fexofenadine; Diphenhydramine; Levocetirizine
4) By Vasodilators: Endothelin Receptor Antagonists; Phosphodiesterase-5 Inhibitors; Prostacyclin Analogues
5) By Short-Acting Beta-2 Agonists (SABA): Albuterol; Levalbuterol; Terbutaline; Fenoterol; Pirbuterol
6) By Other Drug Classes: Monoclonal Antibodies; Enzymes; Antibiotics; Antileukotrienes
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck Sharp & Dohme Limited; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34941

1. Executive Summary

2. Pulmonary Drugs Market Characteristics

3. Pulmonary Drugs Market Trends And Strategies

4. Pulmonary Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pulmonary Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Pulmonary Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Pulmonary Drugs Market Growth Rate Analysis
5.4. Global Pulmonary Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Pulmonary Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Pulmonary Drugs Total Addressable Market (TAM)

6. Pulmonary Drugs Market Segmentation

6.1. Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Other Drug Classes
6.2. Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Other Indications
6.3. Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Retail Pharmacies
Online Pharmacies
Hospitals Pharmacies
6.4. Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Beclomethasone
Budesonide
Fluticasone
Mometasone
Ciclesonide
6.5. Global Pulmonary Drugs Market, Sub-Segmentation Of Long Acting Beta-2 Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Salmeterol
Formoterol
Indacaterol
Olodaterol
Vilanterol
6.6. Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cetirizine
Loratadine
Fexofenadine
Diphenhydramine
Levocetirizine
6.7. Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Endothelin Receptor Antagonists
Phosphodiesterase-5 Inhibitors
Prostacyclin Analogues
6.8. Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists (SABA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Albuterol
Levalbuterol
Terbutaline
Fenoterol
Pirbuterol
6.9. Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Enzymes
Antibiotics
Antileukotrienes

7. Pulmonary Drugs Market Regional And Country Analysis

7.1. Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pulmonary Drugs Market

8.1. Asia-Pacific Pulmonary Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pulmonary Drugs Market

9.1. China Pulmonary Drugs Market Overview
9.2. China Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pulmonary Drugs Market

10.1. India Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pulmonary Drugs Market

11.1. Japan Pulmonary Drugs Market Overview
11.2. Japan Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pulmonary Drugs Market

12.1. Australia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pulmonary Drugs Market

13.1. Indonesia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pulmonary Drugs Market

14.1. South Korea Pulmonary Drugs Market Overview
14.2. South Korea Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pulmonary Drugs Market

15.1. Western Europe Pulmonary Drugs Market Overview
15.2. Western Europe Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pulmonary Drugs Market

16.1. UK Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pulmonary Drugs Market

17.1. Germany Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pulmonary Drugs Market

18.1. France Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pulmonary Drugs Market

19.1. Italy Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pulmonary Drugs Market

20.1. Spain Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pulmonary Drugs Market

21.1. Eastern Europe Pulmonary Drugs Market Overview
21.2. Eastern Europe Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pulmonary Drugs Market

22.1. Russia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pulmonary Drugs Market

23.1. North America Pulmonary Drugs Market Overview
23.2. North America Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pulmonary Drugs Market

24.1. USA Pulmonary Drugs Market Overview
24.2. USA Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pulmonary Drugs Market

25.1. Canada Pulmonary Drugs Market Overview
25.2. Canada Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pulmonary Drugs Market

26.1. South America Pulmonary Drugs Market Overview
26.2. South America Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pulmonary Drugs Market

27.1. Brazil Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pulmonary Drugs Market

28.1. Middle East Pulmonary Drugs Market Overview
28.2. Middle East Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pulmonary Drugs Market

29.1. Africa Pulmonary Drugs Market Overview
29.2. Africa Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pulmonary Drugs Market Competitive Landscape And Company Profiles

30.1. Pulmonary Drugs Market Competitive Landscape
30.2. Pulmonary Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck Sharp & Dohme Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Pulmonary Drugs Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. AstraZeneca plc
31.3. Novartis AG
31.4. GlaxoSmithKline plc
31.5. Mylan N.V.
31.6. Teva Pharmaceutical Industries Ltd.
31.7. Boehringer Ingelheim International GmbH
31.8. Grifols S.A.
31.9. Chiesi Farmaceutici S.p.A.
31.10. Cipla Limited
31.11. Lupin Pharmaceuticals Inc.
31.12. United Therapeutics Corporation
31.13. Mallinckrodt Pharmaceuticals plc
31.14. Glenmark Pharmaceuticals Limited
31.15. Circassia Pharmaceuticals plc

32. Global Pulmonary Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pulmonary Drugs Market

34. Recent Developments In The Pulmonary Drugs Market

35. Pulmonary Drugs Market High Potential Countries, Segments and Strategies

35.1 Pulmonary Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Pulmonary Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Pulmonary Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
250617_r34941_Pulmonary_Drugs_GMR_2025